Cargando…

Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids

BACKGROUND: Targeted anti-HER2 therapy has greatly improved the prognosis for many breast cancer patients. However, treatment for HER2 negative disease is currently still selected from a multitude of untargeted chemotherapeutic treatment options. A predictive test was developed using patient-derived...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halfter, Kathrin, Hoffmann, Oliver, Ditsch, Nina, Ahne, Mareike, Arnold, Frank, Paepke, Stefan, Grab, Dieter, Bauerfeind, Ingo, Mayer, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855689/ https://www.ncbi.nlm.nih.gov/pubmed/27142386 http://dx.doi.org/10.1186/s12967-016-0855-3

Ejemplares similares

Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study
por: Halfter, Kathrin, et al.
Publicado: (2015)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Colonoscopy and polypectomy: beside age, size of polyps main factor for long-term risk of colorectal cancer in a screening population
por: Halfter, Kathrin, et al.
Publicado: (2021)

Therapeutic potential of HERS spheroids in tooth regeneration
por: Duan, Yufeng, et al.
Publicado: (2020)

First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
por: Ettl, Johannes, et al.
Publicado: (2020)

Targeted Chemotherapy of Glioblastoma Spheroids with an Iontronic Pump
por: Waldherr, Linda, et al.
Publicado: (2021)

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
por: Okines, Dr Alicia FC, et al.
Publicado: (2021)

Expanding mammography screening for women aged 40–80 years: evidence from a modeling approach using real-world data
por: Hölzel, Dieter, et al.
Publicado: (2023)

Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro
por: Balalaeva, I. V., et al.
Publicado: (2017)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Risk of metastasis in breast cancer through delay in start of primary therapy
por: Halfter, Kathrin, et al.
Publicado: (2023)

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
por: Lorusso, Vito, et al.
Publicado: (2020)

Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data
por: Engel, Jutta, et al.
Publicado: (2022)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
por: Geyer, Charles E., et al.
Publicado: (2018)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
por: Lucas, Mairi W, et al.
Publicado: (2022)

Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids
por: Rodríguez, Cristina E., et al.
Publicado: (2015)

Effect of Spheroidal Age on Sorafenib Diffusivity and Toxicity in a 3D HepG2 Spheroid Model
por: Eilenberger, Christoph, et al.
Publicado: (2019)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids
por: Gendre, Dylan A.J., et al.
Publicado: (2021)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
por: Müller, Volkmar, et al.
Publicado: (2023)

Response to chemotherapy of EMT6 spheroids as measured by growth delay and cell survival.
por: Twentyman, P. R.
Publicado: (1980)

Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment
por: Däster, Silvio, et al.
Publicado: (2016)

A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies
por: Dadgar, Neda, et al.
Publicado: (2020)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
por: Sánchez-Rovira, P., et al.
Publicado: (2013)

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
por: Haugen, Mads H., et al.
Publicado: (2021)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
por: Kümmel, Sherko, et al.
Publicado: (2018)

Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
por: Lv, Zhi-Dong, et al.
Publicado: (2022)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
por: Urakçı, Zuhat, et al.
Publicado: (2023)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
por: Chen, Hai-long, et al.
Publicado: (2023)

Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids
por: L'Espérance, Sylvain, et al.
Publicado: (2008)

High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately
por: Chen, Wenjin, et al.
Publicado: (2014)

BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1u0ihuhme1vciiummtf1sa62dn